# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-09 (automated)
**Previous monitor report:** 2026-07-08
**Verdict:** One item worth a look — tirzepatide's cardiovascular-outcomes trial (SURPASS-CVOT, NCT04255433) posted results on 07-08. Otherwise a quiet day: no status changes, no FDA action in the last 7 days, all data fresh. Gap analysis is 2 days old and still current.

---

## File System Status

All primary script outputs are present and fresh (≤2 days old):

| File | Last modified | Status |
|------|--------------|--------|
| clinical_trials_latest.json | 2026-07-09 02:06 | Fresh (850 trials) |
| pubmed_recent_latest.json | 2026-07-09 02:06 | Fresh (156 unique papers, 30-day lookback) |
| hub_monitor_report.md | 2026-07-09 02:07 | Fresh (reflects 07-08→07-09 diff) |
| literature_gap_data.json | 2026-07-07 02:13 | Current (2 days) |
| literature_gap_report.md | 2026-07-08 03:07 | Current (1 day) |

Snapshots exist through 2026-07-09 for both trials and PubMed, so day-over-day diffing is intact. Unlike yesterday, `hub_monitor.py` regenerated its own report this cycle and computed the snapshot diffs directly — those match the independent diff below.

**Stale-data note:** `hub_monitor.py` flagged 800 result files older than 14 days — expected, since most are dated daily snapshots retained as history. Not actionable.

---

## Clinical Trial Changes (07-08 → 07-09)

- **New in snapshot:** 5 trials. Four are academic/education studies newly indexed into the "Recently Completed with Results" set (NCT05587348, NCT05565716, NCT05565534, plus recruiting NCT07690163 on new-onset glycemic assessment). The fifth is the notable one — see below.
- **Status changes:** 0
- **Newly posted results (day-over-day on common trials):** 0
- **Removed:** 1 — NCT06094491 *"Virtual Diabetes Group Visits Across Health Systems"* (dropped from CT.gov query results; low priority).

**Worth reviewing — tirzepatide CV outcomes:**
- **NCT04255433** — *Tirzepatide (LY3298176) Compared With Dulaglutide on Major Adverse Cardiovascular Events* (Eli Lilly, Phase 3, SURPASS-CVOT). **Results posted 2026-07-08.** This is the head-to-head MACE trial versus an active comparator (dulaglutide), not placebo — the readout speaks directly to tirzepatide's cardiovascular profile. Evidence level: CT.gov results record = direct primary source **[Certain]** that results are posted; efficacy interpretation requires reading the posted results and any peer-reviewed publication before any claim is asserted.

**Phase 3 landscape:** 48 diabetes trials currently RECRUITING at Phase 3 (up from 42 flagged on 07-08; the increase reflects query/indexing refresh, not six brand-new starts — composition should be spot-checked, not assumed).

**Key-organization Phase 3 trials being tracked (status unchanged):**

- **Vertex** — NCT04786262 & NCT06832410 (VX-880 / zimislecel islet cell therapy), both RECRUITING. VX-264 (NCT05791201) Phase 1/2 ACTIVE_NOT_RECRUITING.
- **Eli Lilly** — Baricitinib beta-cell preservation NCT07222332 & NCT07222137 (RECRUITING); orforglipron program NCT06972472 / NCT06993792 / NCT07613307 / NCT07668336 / NCT06972472; retatrutide NCT06260722 / NCT05929079 / NCT06297603 (all ACTIVE_NOT_RECRUITING).
- **Novo Nordisk** — weekly insulin icodec NCT07076199 (RECRUITING); CagriSema NCT06534411 / NCT07564414 (RECRUITING) plus NCT07282613 (not yet recruiting).
- **Sana Biotechnology** — still no matching trials in the current snapshot. This is now a recurring miss across runs; the query terms likely don't capture Sana's hypoimmune islet program (see Breaking News). Recommend confirming coverage manually.

Evidence level: CT.gov registry data = direct primary source **[Certain]** for status; no efficacy claims asserted here.

---

## PubMed Highlights (30-day lookback, 156 unique papers)

**Cross-domain papers (14 total; highest value).** Papers surfacing in multiple alert domains this cycle:

- **[42419792]** *Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis* — **3 domains** (orforglipron, retatrutide, CagriSema). BMJ, 2026-07-08. A network meta-analysis spanning all three tracked incretin therapies — the single most relevant new paper for the drug-tracking domains. **[Likely]** high value; confirm it is a full NMA and note evidence tier (systematic review = high) on ingest.
- **[42411999]** *Type 1 Diabetes Driven by Residual Recipient T Cells After Hematopoietic Cell Transplant* — T1D Stem Cell Cure + T1D Immunotherapy. Diabetes Care, 2026-07-07.
- **[42387220]** *Overcoming Immunological Barriers in MSC-Derived Insulin-Producing Cells* — T1D Stem Cell Cure + Gene Therapy. Stem Cell Rev Rep, 2026-07-02.
- **[42420766]** *Early Worsening of Diabetic Retinopathy Following Initiation of Hybrid Closed-Loop/AID* — Closed Loop AP + Complications. Diabetes Obes Metab, 2026-07-08. Clinically actionable safety signal worth reading.
- Three teplizumab papers (**42332392, 42302798, 42295172**) cluster on T1D Immunotherapy + teplizumab (expanded-indication commentary in Lancet D&E, Medical Letter, JAAPA).

**Key-therapy mentions this cycle:** dapagliflozin 53 hits / 5 papers; orforglipron 8/5; retatrutide 7/5; teplizumab 6/5; CagriSema 4/4; icodec 4/4; baricitinib 2/2; **zimislecel 0/0** (no new indexed papers — worth noting given Vertex's active Phase 3).

**Volume trends by domain:** AI/ML (212) and Microbiome (172) dominate; T2D GLP-1 (169) and Biomarker (143) strong. Thin domains: Epigenetics (5), LADA (8), Drug Repurpose (8), T1D Stem Cell Cure (12). GLP-1 Pharmacogenomics returned no count — possible empty query; flag for script check.

---

## Gap Analysis Summary (data 2026-07-07, BRONZE validation)

Top under-researched intersections (Gap Score 100, joint pubs 0–1):

1. **Beta Cell Regen × Health Equity** (0 joint) — who gets access to regenerative therapies is unstudied.
2. **Insulin Resistance × Islet Transplant** (1) — IR in graft recipients affects survival; barely studied.
3. **Islet Transplant × Drug Repurposing** (0) — computational screening of immunosuppressants for islet protection unexplored.
4. **Islet Transplant × Health Equity** (0) — access equity for a select-center-only therapy is absent.
5. **Gene Therapy × LADA** (0) — LADA's autoimmune mechanism is a gene-therapy candidate with no crossover work.

**Alignment with Tier 1 doctrine areas:** These gaps sit mostly in Tier 3 domains (Islet Biology, Gene Therapy). The two that map to **Tier 1** contribution areas are **Drug Repurposing Computational Screening** (#3, appears repeatedly across the gap list) and **Literature Synthesis & Gap Analysis** (the analysis itself). Islet-Transplant × Drug-Repurposing is the strongest Tier-1-actionable candidate — it pairs a high-value method (computational screening) with a genuine, verifiable zero-overlap gap. Evidence level: **BRONZE** (single analytical source; the doctrine requires expert confirmation before treating any gap as real vs. a keyword artifact).

---

## Breaking News (web check, last 7 days)

No new FDA action or Phase 3 topline in the trailing 7 days. Context confirmed rather than changed:

- **Orforglipron (Foundayo)** remains FDA-approved (April 1, 2026) for weight management only. Lilly's **type-2-diabetes** submission (ACHIEVE program) is still pending filing this year — no diabetes indication yet. No change since prior runs.
- **Sana Biotechnology** continues to be cited for gene-edited hypoimmune islet cells as a 2026 program to watch — reinforcing the recommendation to fix the trial-query coverage gap above.
- General 2026 landscape items (Vertex stem-cell therapy anticipated approval, once-weekly basal insulin rollout, teplizumab beta-cell preservation) are ongoing, not new events.

Nothing here rises to an actionable alert this cycle.

---

## Recommended Actions

1. **Review the tirzepatide SURPASS-CVOT results (NCT04255433).** Pull the posted CT.gov results record; if a MACE-vs-dulaglutide readout, log it in the tracker and decide whether it warrants a Clinical Trial Intelligence writeup (Tier 1 area). Do not assert efficacy until the results record is read.
2. **Read cross-domain paper [42419792]** (BMJ network meta-analysis of orforglipron/retatrutide/CagriSema) — directly relevant to three tracked domains; strong candidate for ingest at systematic-review evidence tier.
3. **Fix the Sana Biotechnology query gap.** Sana's hypoimmune islet program is repeatedly absent from snapshots. Add sponsor/keyword terms (e.g., "hypoimmune," "SC-islet," "UP421") to `baseline_clinical_trials.py` and re-run.
4. **Check the `GLP-1 Pharmacogenomics` domain query** in `baseline_pubmed_alerts.py` — it returned no count this cycle (possible malformed/empty query).
5. **Re-run gap analysis** — `python project1_literature_gap_analysis.py`. Data is 2 days old (fine now, refresh within the week). Prioritize expert review of **Islet Transplant × Drug Repurposing** as the top Tier-1-actionable BRONZE gap.
6. **Spot-check the Phase 3 RECRUITING jump (42→48).** Confirm whether real new starts or an indexing artifact before treating as growth.

---

*Generated by diabetes-hub-monitor (automated review run). No existing files modified. All new claims labeled with evidence level per Research Doctrine v1.0; trial/PubMed data are direct primary sources [Certain] for existence/status, efficacy interpretations deferred pending source read.*

## Sources
- [Type 1 Diabetes Breakthroughs to Watch in 2026 — Type1Strong](https://www.type1strong.org/blog-post/type-1-diabetes-breakthroughs-to-watch-in-2026)
- [Top Companies Developing Cell Therapies for Diabetes in 2026 — BioInformant](https://bioinformant.com/stem-cells-for-diabetes/)
- [Foundayo (orforglipron) FDA Approval History — Drugs.com](https://www.drugs.com/history/foundayo.html)
- [Oral GLP-1 Orforglipron Performs Well in Phase 3 T2D Trials — Medscape](https://www.medscape.com/viewarticle/oral-glp-1-orforglipron-performs-well-phase-3-t2d-trials-2026a1000jfv)
- [SURPASS-CVOT — NCT04255433, ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04255433)
